Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:SLS News 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,
23 December 2025
·
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy (galinpepimut‑S, “GPS”) is in a Phase 3 AML trial (REGAL), which recently passed an interim safety review
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025, and the momentum accelerated in mid-October. On Friday Oct. 17, SLS closed at $2.14, up roughly 100% year-to-datefinbold.com. In fact, during that day’s session the stock touched a 52-week high of $2.27 (more than 3× its 52-week low of $0.77)marketbeat.com. Trading activity exploded as well – volume spiked to several times the usual level (over 6.7 million shares vs ~2.2M average) amid a flurry of speculative buying. Options
18 October 2025

Stock Market Today

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

7 February 2026
New York, February 7, 2026, 15:20 EST — Market closed. International Business Machines Corp shares closed up 3.12% on Friday at $298.93, giving the stock a firmer finish ahead of Monday’s reopen after a choppy week in U.S. tech. The bounce mattered because it landed on a broad risk-on day that pushed the Dow to a first close above 50,000, after three sessions of losses fueled by anxiety over whether big AI budgets will pay off. “There’s enough evidence that there’s real demand for AI products,” Baird investment strategy analyst Ross Mayfield said. (Reuters) Macro data also helped set the
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop